title: Alteration in serum neural cell adhesion molecule in patients of schizophrenia.
abstract: BACKGROUND
  The neural cell adhesion molecule (N-CAM) plays important roles in neural migration, synaptogenesis and CNS development. Change of N-CAM fragments in CSF of schizophrenic patients was reported previously, and we aimed to detect difference in circulating N-CAM in the serum of schizophrenic patients and healthy controls.
  
  
  METHODS
  Samples were from 14 chronic schizophrenic patients including 3 drug naïve patients and 11 healthy controls. After removal of albumin and globulin, N-CAM fragments were measured by Western blot technique with monoclonal antibody.
  
  
  RESULTS
  N-CAM immunoreactive bands were detected primarily at 180, 140, 120, 75, 68 and 52 kDa. Samples from patients and controls showed similar patterns of bands, but schizophrenic patients showed increases or decreases at some bands intensity compared to healthy controls. The 68 kDa/73-75 kDa bands intensity ratio was substantially elevated in schizophrenic patients (0.262+/-0.14 in patients, 0.065+/-0.04 in controls) especially, the three drug naïve patients had a higher value of this ratio compared to the medicated patients. One drug naïve patient showed a decrease in this ratio after one month of antipsychotic medication.
  
  
  CONCLUSIONS
  The results suggest elevated membrane turnover and/or abnormalities in the regulation of proteolysis of N-CAM in schizophrenia.
authors.affiliation: Asai Hospital, Chiba, and Department of Biomolecular Science, Faculty of Engineering, Gifu University, Japan.
authors.forename: Yoko
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yoshida
authors.forename: Yumi
authors.initials: Y
authors.lastname: Shimada
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ueda
authors.forename: Kunihiko
authors.initials: K
authors.lastname: Asai
mesh_terms: D000328:Adult; D000367:Age Factors; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001569:Benzodiazepines / Q000627:therapeutic use; D015153:Blotting, Western; D002908:Chronic Disease; D003987:Dibenzothiazepines / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D054833:Isoindoles; D008297:Male; D008875:Middle Aged; D008970:Molecular Weight; D019006:Neural Cell Adhesion Molecules / Q000097:blood* / Q000737:chemistry; D000077152:Olanzapine; D020033:Protein Isoforms / Q000097:blood / Q000737:chemistry; D000069348:Quetiapine Fumarate; D018967:Risperidone / Q000627:therapeutic use; D012559:Schizophrenia / Q000097:blood* / Q000188:drug therapy; D013844:Thiazoles / Q000627:therapeutic use
chemical_list: D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D007211:Indoles; D054833:Isoindoles; D019006:Neural Cell Adhesion Molecules; D020033:Protein Isoforms; D013844:Thiazoles; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; D018967:Risperidone; C065533:perospirone; D000077152:Olanzapine